-+ 0.00%
-+ 0.00%
-+ 0.00%

Illumina Invests In MyOme, Announcing Collaboration To Advance Proactive Health Trial Using WGS With AI Risk Models For Chronic, Rare Diseases And Cancer

Benzinga·12/11/2025 14:22:04
Listen to the news

Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention.

SAN DIEGO and MENLO PARK, Calif., Dec. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance MyOme's strategic roadmap including MyOme's Proactive Health (MPH) Trial — a large-scale prospective trial that aims to prove enhanced patient outcomes and substantial cost savings resulting from use of whole-genome sequencing (WGS) combined with MyOme's AI-integrated risk models (IRMs) for common, chronic conditions, cancers, and rare disease.